| Autor: |
Schmitz KS; Department Viroscience, Erasmus MCgrid.5645.2, Rotterdam, the Netherlands., Geers D; Department Viroscience, Erasmus MCgrid.5645.2, Rotterdam, the Netherlands., de Vries RD; Department Viroscience, Erasmus MCgrid.5645.2, Rotterdam, the Netherlands., Bovier TF; Department of Pediatrics, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA., Mykytyn AZ; Department Viroscience, Erasmus MCgrid.5645.2, Rotterdam, the Netherlands., Geurts van Kessel CH; Department Viroscience, Erasmus MCgrid.5645.2, Rotterdam, the Netherlands., Haagmans BL; Department Viroscience, Erasmus MCgrid.5645.2, Rotterdam, the Netherlands., Porotto M; Department of Pediatrics, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.; Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Caserta, Italy., de Swart RL; Department Viroscience, Erasmus MCgrid.5645.2, Rotterdam, the Netherlands., Moscona A; Department of Pediatrics, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.; Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.; Department of Physiology & Cellular Biophysics, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.; Department of Microbiology & Immunology, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA. |
| Abstrakt: |
The ability of SARS-CoV-2 to evolve in response to selective pressures poses a challenge to vaccine and antiviral efficacy. The S1 subunit of the spike (S) protein contains the receptor-binding domain and is therefore under selective pressure to evade neutralizing antibodies elicited by vaccination or infection. In contrast, the S2 subunit of S is only transiently exposed after receptor binding, which makes it a less efficient target for antibodies. As a result, S2 has a lower mutational frequency than S1. We recently described monomeric and dimeric SARS-CoV-2 fusion-inhibitory lipopeptides that block viral infection by interfering with S2 conformational rearrangements during viral entry. Importantly, a dimeric lipopeptide was shown to block SARS-CoV-2 transmission between ferrets in vivo. Because the S2 subunit is relatively conserved in newly emerging SARS-CoV-2 variants of concern (VOCs), we hypothesize that fusion-inhibitory lipopeptides are cross-protective against infection with VOCs. Here, we directly compared the in vitro efficacies of two fusion-inhibitory lipopeptides against VOC, in comparison with a set of seven postvaccination sera (two doses) and a commercial monoclonal antibody preparation. For the beta, delta, and omicron VOCs, it has been reported that convalescent and postvaccination sera are less potent in virus neutralization assays. Both fusion-inhibitory lipopeptides were equally effective against all five VOCs compared to ancestral virus, whereas postvaccination sera and therapeutic monoclonal antibody lost potency to newer VOCs, in particular to omicron BA.1 and BA.2. The neutralizing activity of the lipopeptides is consistent, and they can be expected to neutralize future VOCs based on their mechanism of action. IMPORTANCE SARS-CoV-2, the causative agent of COVID-19, continues to spread globally, with waves resulting from new variants that evade immunity generated by vaccines and previous strains and escape available monoclonal antibody therapy. Fusion-inhibitory peptides may provide an intervention strategy that is not similarly affected by this viral evolution. |
